Articles tagged with Drug Development
Researchers evaluated Tomivosertib's therapeutic potential on AML cells and found it to be highly effective at blocking eIF4E phosphorylation. Combination with Venetoclax resulted in synergistic anti-leukemic responses. The study also identified novel putative MNK1/2 interactors.
Researchers developed a smart collar that delivers praziquantel, a deworming drug, to dogs infected with echinococcosis. The collar reduces the risk of tapeworms in dogs by 0.182 times and 0.336 times compared to control groups.
Researchers developed an AI system that analyzes 3D brain images to diagnose Parkinson's disease stages, providing a more precise diagnosis. The tool combines AI and 3D imaging to estimate severity based on neuronal damage.
A new multicenter study found that continuing antiseizure medication after neonatal seizures stopped did not prevent epilepsy or developmental delays in babies. This contradicts standard practice of extending treatment for months, and highlights the need to reassess standard care for newborns with seizures.
Scientists have uncovered the molecular structure of three major complexes of glutamate receptors in the hippocampus, a region crucial for memory and learning. The discovery has significant implications for treating epilepsy and seizure disorders, as it enables the development of targeted drugs to modulate specific receptor activity.
Researchers at UC3M's 4D-BIOMAP project have developed magneto-active polymers that can alter mechanical properties, stiffness, and shape. These materials could be used in epithelial wound healing stimulation, soft robots, and artificial muscles, revolutionizing biomedical engineering.
Researchers at Aalto University developed a method to determine safe drug doses for children by analyzing organ maturation models. This approach accounts for differences in organ performance between adults and children, reducing bias and increasing efficiency.
The expanded patient-level data will facilitate more efficient clinical trial design, enabling generation of novel drug development tools and solutions. The novel tools and solutions will enable better informed inclusion criteria, endpoint selection, and patient enrichment strategies.
Researchers determined the structure of Glycine Transporter 1, a protein responsible for glycine uptake in neurons. The discovery could lead to developing inhibitors targeting this protein to treat schizophrenia and other psychiatric disorders.
New research highlights the prevalence of animal-derived medications in common treatments, including blood thinners and hormones. Patients who object to using products from animals should be informed about their medication options.
Researchers developed microswimmers that can change direction by heating tiny gold particles, then learned to navigate through a virtual environment via external control and virtual rewards. The findings suggest an optimal speed is key to navigation, with implications for autonomous tasks and collective behavior in biological systems.
The Acute Kidney Injury Project aims to develop improved predictive and detection tools for kidney injury, addressing a global public health concern. The project will focus on developing prognostic tools to identify drug-induced kidney injury, with the goal of improving patient safety during clinical trials and advancing drug development.
Researchers developing standardized platform for organs-on-chips with human cells, aiming to test drugs and food outside a human body. The goal is to link multiple organ chips together to simulate a whole body, eliminating harmful or ineffective drugs earlier in the process.
A new trial shows that immunotherapy drug teplizumab can delay the onset of Type 1 diabetes in people at high risk by an average of five years compared to a placebo. The study, published in Science Translational Medicine, found reduced T-cell damage and improved insulin-producing beta cells in those who received the treatment.
Researchers developed a direct cloning method, CAPTURE, to accelerate large-scale discovery of novel natural products. The method allows for efficient cloning of large genomic fragments, including those with high-GC content or sequence repeats.
A monitoring system based on smartwatches detects movement issues and tremors in Parkinson's patients, allowing for remote monitoring and adjusted medication plans. The platform showed promising results, with 94% match between clinician evaluations and patient data.
Research into INNA-X shows it is effective against rhinovirus, the main cause of the common cold, reducing viral load and inflammation. The nasal spray works by stimulating the innate immune system, making it harder for viruses to take hold.
A recent RAND Corporation report reveals that US prescription drug prices are substantially higher than those in other developed countries, with brand-name drugs costing an average of 3.44 times more. In contrast, unbranded generic drugs account for 84% of US spending but have prices slightly lower than most global peers.
Researchers have discovered an antibody, 2B7, that physically blocks the Non-Structural Protein 1 (NS1) protein, preventing the dengue virus from attaching to cells and slowing its spread. This breakthrough could lead to new treatments for other flaviviruses like Zika and West Nile.
A large-scale study by Bentley University found that 78% of biotech companies completing Initial Public Offerings (IPOs) from 1997-2016 achieved product approvals. The majority of these approved products were small molecule drugs, accounting for 75% of phase 3 products and 78% of approvals.
The global Phase 2/3 study with orally-administered opaganib in patients hospitalized with severe COVID-19 pneumonia has received a second unanimous recommendation to continue, based on an analysis of unblinded safety data from the first 155 patients treated for 14 days. Enrollment is over 60% complete and top-line data expected in Q1/...
A study published in Science Translational Medicine shows that MEK inhibitors can stimulate PAX6 expression in the eye of mice with aniridia, partially normalizing their eye development. Researchers also found that topical administration of the drug enhanced PAX6 and cleared corneas, allowing mice to see better.
RedHill's P2/3 COVID-19 candidate Opaganib has demonstrated reduced thrombosis in a preclinical model of ARDS. The study showed opaganib reduced blood clot length, weight, and total thrombus score in patients with severe respiratory distress syndrome induced by SARS-CoV-2.
Researchers at UC Davis have developed a non-hallucinogenic version of the psychedelic drug ibogaine, which retains therapeutic properties without its serious side effects. The new molecule, TBG, has shown promising positive effects in animal models of depression and addiction.
The FDA's ISTAND program aims to qualify human biology-based drug testing methods, reducing the need for animal testing. Pharmaceutical companies can now use these approaches with confidence, as they will be reviewed and accepted by the FDA.
A research team at RIKEN Center for Biosystems Dynamics Research successfully evolved Escherichia coli under antibiotic pressure, identifying mechanisms and constraints underlying drug resistance. The findings can be used to develop strategies that minimize the chance of bacteria developing resistance.
Researchers evaluated all new COVID-19 vaccines approved by FDA over last decade, analyzing premarket development time, clinical evidence, and safety database size. The study found that vaccine approvals took an average of 10 months, with varying levels of evidence and follow-up durations.
The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) has achieved significant milestones in its first year, thanks to data sharing and collaboration among stakeholders. The platform serves as a centralized infrastructure to support data analysis and aid in the understanding of rare diseases.
Researchers at Karolinska Institutet have identified a key protein called p11 that affects the brain's response to stress, potentially increasing the risk of depression. The study found that mice with low p11 levels react more strongly to stress and exhibit anxiety-like behavior.
PATH will lead an international collaboration to optimize Cry5B protein as an inexpensive, broad-spectrum antiparasitic treatment suitable for adults, children, and pregnant women. The goal is to expand anthelmintic MDA campaigns and reduce the global burden of STH infections.
Researchers found that patients taking HIV and hepatitis B treatment had a 33% lower risk of developing diabetes. The protective effect was replicated in multiple databases, suggesting that these drugs could be repurposed to prevent type 2 diabetes.
The review highlights the need for clear scientific and pharmaceutical standards when developing live biotherapeutic products. Key challenges include ensuring quality, demonstrating safety, and evaluating efficacy. The PRI's publication provides a framework for stakeholders in microbiome-based product development.
Researchers at Indiana University School of Medicine are testing the use of tezampanel, a novel antagonist at glutamate receptors, to treat opioid withdrawal syndrome and other addictions. The project aims to develop breakthrough medications more rapidly than traditional mechanisms, with potential approval from NIDA and FDA.
Scientists developed three-dimensional heart organoids resembling the developing heart using mouse embryonic stem cells and fibroblast growth factor 4 (FGF4). The organoids exhibit functional properties similar to their in vivo counterparts, offering a promising biomimetic model for studying heart development and testing novel drugs. T...
Researchers are developing CBD-based treatments for chronic inflammatory diseases, such as lupus and multiple sclerosis. Pharmaceutical companies are also working to enhance the potency of CBD by creating more potent derivatives that can be absorbed by the body.
A study found that taking at least one anticholinergic drug increases the risk of developing mild cognitive impairment by 47%, particularly in those with genetic risk factors for Alzheimer's disease. The study suggests reducing anticholinergic use may help prevent negative effects on thinking skills.
Biomechanical engineers at Tohoku University developed a formula to describe permeability of rubbed skin. The study found that mechanical rubbing causes gaps in the skin's barrier function and can potentially allow transdermal virus infection. Further research is needed to determine the risk of skin damage from face masks.
Researchers have discovered stable, synthetic STING agonists that induce anticancer immune responses in mice. These non-nucleotide small molecule STING agonists show robust anti-tumor activities and may represent an attractive approach for targeting the STING pathway.
Researchers at IRB Barcelona have been awarded an ERC grant to develop new medications targeting senescent cells, which contribute to fibrotic diseases. The goal is to create senolytics that selectively eliminate damaged cells, potentially preventing age-related diseases.
The FDA has issued a positive response to C-Path's biomarker panel for detecting acute drug-induced skeletal muscle injury in phase 1 clinical trials. The panel, developed by C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium, uses four molecular biomarkers to aid in the detection of this condition.
Researchers developed a novel EEG system that can measure brain activity from multiple adult zebrafish simultaneously, opening up new possibilities for cheaper and faster drug screening for neurological disorders. This study successfully mapped changes in brain signals during epileptic attacks and demonstrated the efficacy of an anti-e...
Researchers found that individuals with stronger connections between frontal cortex and striatum in two distinct brain networks were more resilient to drug addiction. These brain circuits are involved in goal-directed behavior and habit regulation, suggesting potential strategies for preventing or treating addiction.
Researchers have discovered a compound, tartrolon E, that effectively kills multiple parasites responsible for various infections, including malaria, toxoplasmosis, and cryptosporidiosis. The compound is found in the gills of wood-eating clams and has shown promise in killing these parasites in vitro and in animal studies.
Researchers at Waseda University have successfully developed a method for the total synthesis of cotylenin A, a plant growth regulator with promising bioactivity as an anti-cancer agent. The new method allows for the production of a stable and effective anticancer drug without the side effects associated with traditional treatments.
Critical Path Institute (C-Path) has been awarded a U.S. Food and Drug Administration (FDA) contract to develop novel clinical outcome assessments for pediatric asthma. The project aims to create patient-focused drug development tools for children with asthma.
Researchers compared federal and foundation funding for sickle cell disease and cystic fibrosis, finding that higher funding was associated with increased research productivity and faster drug development. The study suggests that increasing funding could improve treatment options for these two diseases.
The new journal 'Coronaviruses' will publish original research, letters, reviews, and case reports on all aspects of coronaviruses. It will be essential reading for virologists, epidemiologists, microbiologists, and healthcare workers interested in the latest information about coronaviridae.
Researchers estimated that it costs $2.6 billion to develop and commercialize a single new drug or biologic between 2009 and 2018. The study used publicly available data on research and development expenditures for these medicines.
While the number of treatments for rare diseases affecting children has grown, nearly 7,000 conditions still lack treatment options. Federal incentives are being used more often to expand use of existing drugs rather than creating new ones.
The new journal will publish peer-reviewed articles on end-of-life care and relief of suffering, focusing on improving quality of life for patients and their families.
The Wyss Institute's Human Body-on-Chip platform uses fluidically-linked systems of multiple human Organ Chips to predict drug pharmacokinetics and pharmacodynamics. The system quantitatively predicts drug behavior across the entire linked system, offering alternatives to animal tests and improving drug development efficiency.
Researchers have developed a method to grow snake venom gland cells as organoids, producing active toxins. The lab-grown mini glands can be grown from multiple species and maintained indefinitely, holding promise for reducing the devastating impact of snakebites.
Researchers at Stanford University have developed a new kind of cancer drug inspired by antiviral treatments. Tests in mice show that these drugs can shrink tumors and prevent their spread, targeting cellular processes used by both viruses and some cancer cells.
A new wearable lithium monitor developed by the University of Surrey has the potential to revolutionize the treatment of bipolar disorder. The device can detect lithium levels and potentially provide warning signals for high levels, reducing the risk of toxicity.
The MagLev method uses magneto-Archimedes levitation to separate and isolate different drugs from sample mixtures, allowing for precise identification. The technique can distinguish between up to seven substances simultaneously and has the potential to complement or replace existing portable drug identification techniques.
The US Department of Defense has awarded the University of Kansas $2.5 million to advance seismic technology for detecting abandoned mines and tunnels. The research will focus on improving seismic data quality and detection efficiency, with tests conducted in known tunnels in the United States and abroad.
The American Thoracic Society has published a new clinical guideline for the treatment and prevention of drug-resistant tuberculosis, emphasizing the use of all-oral regimens. The guideline also recommends treatment for all contacts of MDR-TB patients and provides evidence-based guidance for pregnant women with MDR-TB.
Researchers developed a combination gene therapy treating four age-related diseases in mice, including heart failure, kidney failure, diabetes, and obesity. The treatment showed significant improvements, reversing or completely eliminating disease symptoms in obese and diabetic mice.
Researchers from SUTD developed syringe-injectable biomaterials with unprecedented capabilities to handle nanosheets. The nanosheets demonstrated syringe-injectability, self-expandability, conformability, and guidability in an external magnetic field.
Researchers discovered a single nucleotide mutation in P. aeruginosa that caused rapid resistance to ceftolozane-tazobactam and partial resensitization to carbapenems and piperacilline-tazobactam. This finding may enable the use of these antibiotics in treating extremely drug-resistant P. aeruginosa cases.